Drug Profile

HBM 7575

Alternative Names: HBM-7575; SKB-575

Latest Information Update: 31 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Harbour BioMed; Sichuan Kelun-Biotech Biopharmaceutical
Class Anti-inflammatories; Antiasthmatics; Bispecific antibodies; Skin disorder therapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jul 2026 Sichuan Kelun-Biotech Biopharmaceutical plans a phase I trial for Asthma (Treatment-experienced) in China (SC), in July 2026 (NCT07732023)
15 Jul 2026 National Medical Products Administration (NMPA) approves IND application for HBM 7575 in Asthma
15 Jul 2026 Clinical trials in Asthma in China (SC)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com